Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Lupin Limited ( (IN:LUPIN) ).
Lupin Limited announced key decisions from its recent board meeting, including the reappointment of Ms. Vinita Gupta as CEO and Mr. Ramesh Swaminathan as Executive Director, Global CFO & Head of API Plus SBU, both for an additional five-year term. Additionally, the company plans to transfer its OTC Consumer Healthcare Business to a new wholly owned subsidiary, and to establish Lupinlife Consumer Healthcare Limited. The board also approved the formulation of an Employee Stock Option Scheme to benefit eligible employees, pending necessary approvals. These strategic moves are expected to enhance Lupin’s operational efficiency and market presence, especially in the consumer healthcare segment.
More about Lupin Limited
Lupin Limited is a major player in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of a wide range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The company is headquartered in Mumbai, India, with a significant presence in the global market.
YTD Price Performance: -8.25%
Average Trading Volume: 19,249
Current Market Cap: 1004.1B INR
Learn more about LUPIN stock on TipRanks’ Stock Analysis page.